XML 22 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Operating activities:    
Net loss $ (125,180,000) $ (66,349,000)
Adjustments to reconcile net loss to net cash used for operating activities:    
Stock-based compensation expense 18,697,000 8,512,000
Depreciation and amortization 793,000 498,000
Amortization of Debt Discount (Premium) 510,000 463,000
Amortization of premium on short-term investments 219,000
Gain on disposal of property and equipment (118,000)
Changes in operating assets and liabilities:    
Inventory (1,983,000)
Prepaid expenses and other assets 428,000 (993,000)
Accounts payable 2,790,000 186,000
Accrued clinical liabilities 4,608,000 1,356,000
Accrued payroll and employee-related liabilities 3,813,000 658,000
Other accrued liabilities (271,000) 411,000
Net cash used for operating activities (95,576,000) (55,376,000)
Investing activities:    
Purchases of short-term investments (43,318,000)
Maturities of short-term investments 55,829,000
Purchases of property and equipment (2,446,000) (783,000)
Proceeds from sale of property and equipment 241,000
Net cash provided by (used for) investing activities 10,065,000 (542,000)
Financing activities:    
Proceeds from purchases under the Employee Stock Purchase Plan 251,000 118,000
Proceeds from stock option exercises 5,720,000 7,915,000
Proceeds from issuance of promissory note payable 50,000,000
Net proceeds from sale of common stock 128,199,000
Net cash provided by financing activities 55,971,000 136,232,000
Net (decrease) increase in cash and cash equivalents (29,540,000) 80,314,000
Cash and cash equivalents at beginning of period 75,180,000 72,675,000
Cash and cash equivalents at end of period 45,640,000 152,989,000
Supplemental disclosure of cash flow information:    
Interest paid $ 622,000